Moderna Inc (MRNA)vsNeuraxis, Inc. (NRXS)
MRNA
Moderna Inc
$214.17
+2.98%
HEALTHCARE · Cap: $87.04B
NRXS
Neuraxis, Inc.
$7.57
+2.85%
HEALTHCARE · Cap: $92.93M
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 41810% more annual revenue ($2.23B vs $5.32M). MRNA leads profitability with a -141.4% profit margin vs -144.4%. NRXS earns a higher WallStSmart Score of 22/100 (F).
MRNA
Avoid21
out of 100
Grade: F
NRXS
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$214.16
$79.45 discount
Margin of Safety
-42.6%
Fair Value
$3.26
Current Price
$7.57
$4.31 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
Revenue surging 115.7% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Trading at 12.6x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Trading at 14.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bull Case : NRXS
The strongest argument for NRXS centers on Revenue Growth, Debt/Equity. Revenue growth of 115.7% demonstrates continued momentum.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Bear Case : NRXS
The primary concerns for NRXS are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRNA profiles as a turnaround stock while NRXS is a hypergrowth play — different risk/reward profiles.
NRXS carries more volatility with a beta of 1.36 — expect wider price swings.
NRXS is growing revenue faster at 115.7% — sustainability is the question.
NRXS generates stronger free cash flow (-1M), providing more financial flexibility.
Bottom Line
NRXS scores higher overall (22/100 vs 21/100) and 115.7% revenue growth. MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Neuraxis, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
NeurAxis, Inc. is a neuromodulation therapy device company in the United States. The company is headquartered in Versailles, Indiana.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?